NasdaqGS - Nasdaq Real Time Price USD

AN2 Therapeutics, Inc. (ANTX)

Compare

1.4300

-0.0500

(-3.38%)

At close: December 13 at 4:00:01 PM EST

1.4900

+0.06

(+4.20%)

After hours: December 13 at 6:12:35 PM EST

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

As the U.S. stock market experiences a positive uptick with major indices like the Dow Jones and S&P 500 showing gains, investors are increasingly looking for opportunities beyond traditional blue-chip stocks. Penny stocks, often associated with smaller or newer companies, continue to offer intriguing possibilities for those willing to explore beyond well-known names. Despite being considered a niche area of investment today, these stocks can still present significant growth potential when...

Simply Wall St. 23 days ago

IMRX

WDH

ANTX
-3.38%
AN2 Therapeutics to Participate at Upcoming Investor Conferences

MENLO PARK, Calif., November 14, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that company management will participate in two upcoming investor conferences in December.

Business Wire last month

ANTX
-3.38%
AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

MENLO PARK, Calif., November 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the quarter ended September 30, 2024 and provided an update from its ongoing analysis of data from the Phase 2 portion of the EBO-301 trial.

Business Wire last month

ANTX
-3.38%
AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

MENLO PARK, Calif., October 17, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that the company has received a second year continuation of a research grant from the Bill & Melinda Gates Foundation to discover novel, boron containing small molecules for the treatment of tuberculosis (TB) and malaria.

Business Wire last month

ANTX
-3.38%
AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

MENLO PARK, Calif., August 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that Eric Easom, Co-Founder, Chairman, President and CEO will present at the H.C. Wainwright 26th Annual Global Investment Conference.

Business Wire 3 months ago

ANTX
-3.38%
AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.

Zacks 3 months ago

ANTX
-3.38%
ARCT

FULC
AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

MENLO PARK, Calif., August 16, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has adopted a limited duration stockholder rights plan, which is scheduled to expire on August 15, 2025.

Business Wire 3 months ago

ANTX
-3.38%
AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., August 13, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today reported financial results for the quarter ended June 30, 2024.

Business Wire 3 months ago

ANTX
-3.38%
Top Midday Decliners

Top Midday Decliners

PREMIUM
MT Newswires 4 months ago

ANTX
-3.38%
TLS
Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce

On Thursday, AN2 Therapeutics, Inc. (NASDAQ:ANTX) released topline results from the Phase 2 part of the EBO-301 Phase 2/3 study of epetraborole on top of an optimized background regimen (OBR) in treatment-refractory mycobacterium avium complex (MAC) lung disease. The Phase 2 part of the study met its primary objective of demonstrating the potential validation of a novel patient-reported outcome (PRO) tool and a higher PRO-based clinical response rate in the epetraborole + OBR arm (39.5%) vs. pla

Benzinga 4 months ago

ANTX
-3.38%
AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

The company stock was down by over 22.7% in premarket trading as AN2 shared trial termination plans for epetraborole.

Pharmaceutical Technology 4 months ago

ANTX
-3.38%
AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell

AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell

PREMIUM
MT Newswires 4 months ago

ANTX
-3.38%
$AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease$

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

MENLO PARK, Calif., August 08, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform today announced topline results from the Phase 2 part of the EBO-301 Phase 2/3 study evaluating epetraborole on top of an optimized background regimen (OBR) in treatment-refractory MAC lung disease.

Business Wire 4 months ago

ANTX
-3.38%
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 5 months ago

ANTX
-3.38%
Intuit initiated, Charter downgraded: Wall Street's top analyst calls

Intuit initiated, Charter downgraded: Wall Street's top analyst calls

The Fly 5 months ago

ANTX
-3.38%
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround

AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks 6 months ago

ANTX
-3.38%
AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., May 14, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the quarter ended March 31, 2024.

Business Wire 6 months ago

ANTX
-3.38%
AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif., March 28, 2024--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2023.

Business Wire 8 months ago

ANTX
-3.38%
13 Best Falling Stocks To Buy Right Now

In this piece, we will take a look at the 13 best falling stocks to buy now. If you want to skip our coverage of the latest stock market news, then you can take a look at the 5 Best Falling Stocks To Buy Right Now. The start of the year has seen some stocks […]

Insider Monkey 9 months ago

PETS

LUNRW

BE
UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment

AN2 Therapeutics said on Monday it will pause further enrollment in a mid-to-late-stage study testing its experimental drug to treat a type of bacterial lung infection, citing potentially lower-than-expected efficacy. The company was conducting a mid-stage study testing epetraborole, a once-daily oral drug to treat MAC lung disease, caused by bacterial infection. AN2 said the decision to pause enrollment will give time to further evaluate the study data and it expects to announce top-line results from the study in the summer.

Reuters 9 months ago

ANTX
-3.38%

Performance Overview

Return	ANTX	S&P 500
YTD	-93.02%	+26.86%
1-Year	-92.96%	+30.31%
3-Year	-91.51%	+28.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AN2 Therapeutics, Inc. (ANTX)

Immuneering Leads The Pack Of 3 US Penny Stocks To Monitor

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline

AN2 Therapeutics Receives Continuation Grant to Discover Novel Boron Based Therapies for Tuberculosis (caused by Mycobacterium tuberculosis) and Malaria

AN2 Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AN2 Therapeutics (ANTX) Plunges 66% in a Month: Here's Why

AN2 Therapeutics Adopts Limited Duration Stockholder Rights Plan

AN2 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business and Scientific Highlights

Top Midday Decliners

Lung Disease Focused AN2 Therapeutics' Lackluster Data Prompts To Stop Phase 3 Study Of Lung Infection Candidate, Halves Workforce

AN2 slashes staff by 50% after lead antibiotic flunks in Phase II/III trial

AN2 Therapeutics to Discontinue Clinical Study of Lung Disease Drug Candidate Epetraborole; Shares Plunge Pre-Bell

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

Intuit initiated, Charter downgraded: Wall Street's top analyst calls

Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights

13 Best Falling Stocks To Buy Right Now

UPDATE 1-AN2 Therapeutics to pause lung disease study enrollment

Performance Overview